Mark Bunnage talks to Leanne Marle about pharmaceuticals, chemologics and economics
Mark Bunnage is executive director of worldwide medicinal chemistry at Pfizer in Sandwich, UK. His areas of responsibility include chemistry leadership for regenerative medicine. He is also a member of the Executive Committee of the European Federation for Medicinal Chemistry (EFMC) and an editorial board member for MedChemComm.
What led you into a career in medicinal chemistry?
I did a doctorate in organic chemistry at the University of Oxford, UK, followed by a post doc in total synthesis in the US. I guess I wanted to apply my skills as an organic chemist to help come up with new medicines – it seemed a really exciting way to put my training and skills to good use. This attracted me to the pharmaceutical industry and to join Pfizer.
What do you find most exciting about medicinal chemistry?
It feels a great privilege to be able to design and synthesise molecules that have never existed before. It is a genuine invention and very exciting to discover new molecules that can modulate human biology to potentially treat disease. This is a great way to apply chemistry and one of the best things about my job is that every day I’m learning new science. The field of medicinal chemistry is evolving quite significantly – so it’s a constant learning environment which is great fun. But the ultimate success is new medicines which can help people so it’s motivating from both the science and the application.
What projects are you working on at the moment?
One of the things we’re working on at the moment is regenerative medicine and the potential of stem cells as therapies. There’s a great opportunity for chemistry to influence this area of research by identifying small molecules that can modulate how stem cells behave. This could be to help generate viable cell therapy products or to find small molecule oral drugs that can influence stem cells to become new cell types and cause regeneration. It’s a cutting edge area in which chemistry is playing an important role.
One project the regenerative medicine group is working on is the treatment of blindness caused by age related degeneration of the cells in the eye. Basically if you could get a cell therapy to replace the retinal pigmented epithelial cells you could potentially restore sight.
What are the current challenges facing drug discovery?
Everyone recognises that the pharmaceutical industry has significant productivity challenges in terms of the number of new drug approvals each year relative to the R&D investment. One of the big reasons that we’ve not been as successful as we might is that we don’t always select the right target, so you can put a lot of investment in and take a quality molecule all the way to a Phase II clinical study but it doesn’t work. As an industry we’ve got to get much better at selecting molecular targets that can really influence disease. We really need to embrace chemical biology because the tools of chemical biology can help make the link between target and disease, and there are some cracking breakthroughs in this area of science that can now be applied in that sense.
This is why we’ve established a dedicated chemical biology group at Pfizer in Sandwich to really apply chemical biology with that aim. Selecting the target to work on is probably the most important decision we make and chemical biology can help with that. In addition, we are also applying the synthetic approaches of chemical biology to generate novel ‘chemologic’ therapeutics that are at the interface between small molecules and large.
What achievement are you most proud of?
One project that I’ve been involved in and that I’m excited about is a new treatment for respiratory disease that is in Phase II trials and is looking promising. There is still a major medical need to treat diseases such as asthma and chronic obstructive pulmonary disease and we’ve hopefully got quite an interesting inhaled product that will make a good addition to treatment options for patients.
You’re on the Editorial Board for the new RSC Journal MedChemComm, how did you get involved?
I’m also involved with the EFMC and the RSC approached us when they were thinking about a medicinal chemistry journal, so we partnered with the RSC to bring forward MedChemComm. We recognised it as a real opportunity for a quality new journal in the field of medicinal chemistry, and particularly one that perhaps helps to drive the scientific agenda within our discipline by covering traditional medicinal chemistry but also going beyond this to illustrate some of the ways that medicinal chemistry is evolving. I was very excited about the opportunity and that’s why I agreed to join the Editorial Board.
As a child, what did you want to be when you grew up?
Well sadly, what I wanted to be when I was a teenager was an economist, which I now look back in horror at the thought of this! But thankfully I saw the light when I studied A-Level Chemistry and saw that there was much more fun to be had in chemistry than in economics. Especially with recent events I’m really glad I didn’t end up in economics!
Download his first (but not last) MedChemComm paper
Small molecule modulation of stem cells in regenerative medicine: recent applications and future direction
Timothy E. Allsopp, Mark E. Bunnage and Paul V. Fish, Med. Chem. Commun., 2010, 1, 16
DOI: 10.1039/c0md00055h
See here the original interview
